CAPA Survival Playbooks — Kandih Bioscience A CAPA that does not result in a Design History File (DHF) update is not effective in FDA’s eyes.From an inspection perspective, CAPA is expected to feed design controls. If real-world failures do not change design inputs, risk analyses, or verification strategies documented in the DHF, FDA assumes the […]
Category: Uncategorized
FDA Expects CAPAs to Feed Design Controls
CAPA Survival Playbooks — Kandih Bioscience From an inspection perspective, a CAPA that stops in QA without informing design inputs, risk management, or validation is incomplete. Administrative closure does not demonstrate learning or restored control; only changes to design and risk assumptions do. When CAPAs Stop at QA, Inspections Don’tOne of the most reliable predictors […]
The Complaint-to-CAPA Mapping Checklist
CAPA Survival Playbooks — Kandih Bioscience Complaint-to-CAPA mapping is a risk-interpretation system, not an administrative checklist.FDA evaluates whether complaint signals are consistently interpreted, escalated, or deferred based on documented risk logic. If the linkage between complaint and CAPA cannot be explained deterministically, FDA treats it as loss of governance—regardless of documentation completeness. Why “End-of-Process” Checklists […]
Do You Trend Complaints Before CAPA?
Yes—FDA expects complaint trending before CAPA initiation.From an inspection perspective, complaint trending is a diagnostic function, not an effectiveness check. If trending only occurs after CAPA opens, FDA assumes the escalation decision was not risk-informed and that the system reacted without understanding the signal. Why This Question Matters More Than Most Teams Realize If CAPA […]
Complaint → Weak Root Cause → Repeat 483
CAPA Survival Playbooks — Kandih Bioscience Repeat FDA 483 observations almost always mean the original root cause was wrong.From an FDA enforcement perspective, recurrence equals misdiagnosis. If the root cause did not explain how the system failed—or why it could fail again—CAPA did not restore control, regardless of how clean the documentation looked. Why “Tidy” […]
Where CAPA Actually Sits: Complaints → Design → CMOs
CAPA Survival Playbooks — Kandih Bioscience CAPA does not sit in QA.From an FDA inspection perspective, CAPA sits at the intersection of complaints, design controls, supplier/CMO oversight, and management review. If CAPA is positioned downstream—after complaints are closed, designs are frozen, or suppliers are “handled”—inspectors interpret the system as reactive and ineffective, regardless of documentation […]
Where Do Your CAPAs Originate Most?
CAPA Survival Playbooks — Kandih Bioscience CAPAs Don’t Fail at Closure—They Fail at the Source Most CAPA programs don’t fail because teams can’t write corrective actions.They fail because organizations never ask—or cannot clearly answer—a far more uncomfortable question: Where do our CAPAs actually come from? Inspection after inspection, FDA sees the same pattern: CAPAs are […]
CAPA ≠ Paperwork. It’s a Risk-Control Feedback Loop
CAPA Survival Playbooks — Kandih Bioscience One of the most common inspection surprises plays out the same way every time:the CAPA file is immaculate—signed, dated, closed on schedule—yet the inspection ends with a Form 483. That disconnect is not subtle. It reflects a fundamental misunderstanding of what CAPA is designed to do. Many organizations still […]
CAPA Failures as Evidence of a Broken Risk-Control System
(How FDA documents system collapse, not paperwork gaps) FDA consistently uses CAPA failures as proxy evidence that a firm’s end-to-end risk-control architecture is nonfunctional. For medical devices, this is most often cited as a violation of 21 CFR 820.100(a). For drugs and combination products, the same systemic failure is documented through CGMP investigation and CAPA […]